[ad_1]
“These are human lives, we cannot accept the rules of the game of ‘who gets it, bites’. It may work for a polar butcher, but not in the European Union,” said Stella Kiriakidis, European health commissioner at AstraZeneca. , a vaccine company Transportation difficulties. He said the European Commission was protecting the interests of coronavirus vaccines in investment deals with manufacturers and European taxpayer money. He also said that
his body has yet to receive a satisfactory explanation from the company as to why the vaccine is being sent to the EU member states.
According to him, the contract with AstraZeneca stipulates that the company must deliver the vaccine from four plants, two of which are in the UK and two are in Belgium. He also said Brussels would not accept the explanation from AstraZeneca CEO Pascal Soriot that vaccines produced in British plants would be reserved for UK residents under an agreement the company had signed with British leadership three months after EU contracts before signing.
The Commissioner noted that the vaccine manufacturer had a “moral, social and contractual obligation” to supply vaccines to EU countries at the right time and in the right quantities.
Reminded me that
the European Commission has signed ex ante market-based agreements to ensure in advance that companies create the conditions for adequate production capacity.
“It is against the terms of the contracts if the company cannot produce enough vaccines,” he said, and asked AstraZeneca to fulfill its obligations to restore confidence.
The British-Swedish company announced on Friday that it is slowing delivery of vaccines to EU member states due to difficulties in the manufacturing process.
The European Medicines Agency is expected to make a decision on Friday on a recommendation on the EU suitability of AstraZeneca and the University of Oxford’s anti-coronavirus product. In late August, the European Commission signed a contract with the company to purchase 300 million doses of the vaccine.
[ad_2]
